Navigation Links
PSA Reading Could Predict Post-Radiation Survival

Rising level in prostate cancer patients may call for more treatment, study finds

WEDNESDAY, Nov. 4 (HealthDay News) -- Prostate cancer patients whose prostate-specific antigen (PSA) levels rise within 18 months after radiotherapy have an increased risk of death, say U.S. researchers.

Their study included more than 2,100 patients with clinically localized prostate cancer who experienced biochemical failure (lowest PSA level plus 2 nanograms per milliliter) after treatment. The median interval between treatment and biochemical failure was 35.2 months, but 19 percent of patients developed biochemical failure at 18 months or less.

Five-year, cancer-specific survival for patients who developed biochemical failure within 18 months was 69.5 percent, compared with 89.8 percent for those who developed biochemical failure more than 18 months after treatment.

The study was to be presented Wednesday at the annual meeting of the American Society for Radiation Oncology in Chicago.

"PSA is the gold standard for following prostate cancer patients after they receive radiation or surgery. But we haven't known if having PSA rise sooner means a patient has a greater danger of dying of prostate cancer, though it seems logical," study leader Dr. Mark K. Buyyounouski, a radiation oncologist at the Fox Chase Cancer Center in Philadelphia, said in a news release from the center.

"Now we can use the simple criteria from this study, which is widely available for anyone who has PSA testing, to identify men who have a greater than 25 percent chance of dying from prostate cancer in the next five years. That is huge. There is nothing else that can do that."

Currently, biochemical failure alone doesn't prompt treatment. Doctors usually wait until a patient's PSA reaches a high level or there is some other evidence of tumor spread.

This study suggests that treatment can begin "far sooner without waiting for other signs or symptoms of prostate cancer," Buyyounouski said. "If a patient has biochemical failure at 16 months, rather than wait and learn later that the PSA is rising sharply and risk the development of distant metastasis, therapy can be started sooner based on the increased risk of death."

More information

The American Cancer Society has more about prostate cancer.

-- Robert Preidt

SOURCE: Fox Chase Cancer Center, news release, Nov. 4, 2009

Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. HCV and HBV spreading more slowly among injection drug users in San Francisco
2. ClassMate Reader - Portable reading system supports K-12 students with reading difficulties
3. Sound training rewires dyslexic childrens brains for reading
4. Diagnostic Mammogram Readings Vary by Radiologist
5. VA Salutes Volunteers Spreading Holiday Cheer
6. Optimal Readings Appoints Operations Veteran Rita Edwards as SVP Clinical Operations
7. Optimal Readings Selected to Present at CEDs 25th Annual Venture Conference
8. New CDC Study Shows Smoke-Free Laws Spreading Across U.S. and Should Spur Remaining States to Take Action
9. Who Knew You Could Learn to Lose Weight by Reading an Enjoyable Novel?
10. Formula Puts Doctor, Patient Glucose Readings on Same Page
11. ECG Reading May Predict Death, Rehospitalization Risk
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company ... destruction of targeted tissues, announced three leadership team developments today:   ... PhD ... ... Veteran medical device executive Josh ...
Breaking Medicine Technology: